GlassScriptPhysician profile
Clinton Ellingson
NPI 1326332776
$4,044.22
in general payments reported to CMS, 2019-2025
19 companies · $641 in 2025
The $641 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $90.48 · 2021: $519 · 2022: $733 · 2023: $735 · 2024: $924 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.49 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,308.95 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $529.95 | 2019-2025 | Vabysmo, Lucentis, Susvimo |
| Bausch & Lomb Americas INC. | $327.35 | 2022-2025 | Stellaris, Stellaris Elite, Envista Envy Iol |
| Abbvie INC. | $321.93 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $283.10 | 2022-2025 | Syfovre |
| Dutch Ophthalmic, USA | $206.76 | 2021-2023 | Eva, Combined Machine, Tissueblue |
| Alcon Vision LLC | $203.99 | 2019-2024 | Ngenuity, Constellation |
| Alimera Sciences, INC. | $144.69 | 2019-2024 | Iluvien, Yutiq |
| Coherus Oncology, INC. | $140.97 | 2024 | |
| Astellas Pharma US INC | $136.30 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $132.55 | 2019-2021 | |
| Genentech, INC. | $102.11 | 2023 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $53.28 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $42.56 | 2019 | |
| Eyepoint US, INC. | $33.77 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.30 | 2019 | |
| Neurotech Pharmaceuticals, INC. | $24.50 | 2025 | |
| Aerie Pharmaceuticals, INC. | $12.56 | 2021 | |
| Quidel Corporation | $9.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Ellingson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.